» Articles » PMID: 25714660

Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis

Overview
Publisher Mary Ann Liebert
Date 2015 Feb 26
PMID 25714660
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In this review we discuss the current literature on the effects of type I interferons (IFN) and their downstream effectors on vascular growth in experimental models in vitro and in vivo. In addition to its well-documented role in angiogenesis, that is, the growth of new capillaries from existing vessels, we will also describe emerging evidence and mechanisms by which type I IFN may inhibit arteriogenesis, that is, the expansive remodeling of existing collateral arteries. Crucial in both processes is the common role of circulating monocytes, which are known to act as pivotal cellular modulators in revascularization through secreted chemokines, proteases, and growth factors. These secreted molecules, which are all modulated by IFN signaling, act via degradation of the extracellular matrix and by stimulating the proliferation of vascular smooth muscle cells and endothelial cells. Thus, next to the antiviral and immunomodulatory activities of type I IFNs, a potent role of IFN-β as modulator of revascularization is now emerging and may be considered a potential clinical target for the stimulation of angiogenesis and arteriogenesis in ill-perfused tissues.

Citing Articles

Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.

Sarfraz A, Sarfraz Z, Bano S, Sarfraz M, Jaan A, Minhas A J Community Hosp Intern Med Perspect. 2024; 14(2):58-66.

PMID: 38966504 PMC: 11221457. DOI: 10.55729/2000-9666.1308.


Platelet activation: a promoter for psoriasis and its comorbidity, cardiovascular disease.

Jiang Z, Jiang X, Chen A, He W Front Immunol. 2023; 14:1238647.

PMID: 37654493 PMC: 10465348. DOI: 10.3389/fimmu.2023.1238647.


Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy.

Schunke J, Mailander V, Landfester K, Fichter M Int J Mol Sci. 2023; 24(15).

PMID: 37569548 PMC: 10419017. DOI: 10.3390/ijms241512174.


SerpinG1: A Novel Biomarker Associated With Poor Coronary Collateral in Patients With Stable Coronary Disease and Chronic Total Occlusion.

Chen S, Li L, Wu Z, Liu Y, Li F, Huang K J Am Heart Assoc. 2022; 11(24):e027614.

PMID: 36515245 PMC: 9798810. DOI: 10.1161/JAHA.122.027614.


Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review.

Dauvergne M, Buob D, Rafat C, Hennino M, Lemoine M, Audard V Clin Kidney J. 2021; 14(12):2563-2572.

PMID: 34950468 PMC: 8690152. DOI: 10.1093/ckj/sfab114.